METHOD FOR PREDICTING RISK OF PROGRESSION OF PRIMARY NON-HODGKIN'S LYMPHOMAS WITH BONE MARROW INVOLVEMENT Russian patent published in 2018 - IPC G01N33/48 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncology and hematology, and can be used to predict the risk of progression of primary B-cell non-Hodgkin's lymphomas with bone marrow damage. Method includes investigation of ploidy and kinetics of the cell cycle by flow cytometry, as well as determining the percentage of blast cells in the hemogram, that at the stage of planning the tactics of therapy, the patient is subjected to DNA-cytometry of the bone marrow with the determination of the cytokinetic index, determination of ploidy and percentage of blast cells in peripheral blood, then risk of progression of primary B-cell non-Hodgkin's lymphomas with bone marrow damage is calculated by the formula P = (1 + 2.72^{-(-3.09 + 0.19×CKI + 3.18×BC + 1.55×A)})^-1, where P is the probability of the onset of disease progression, taking a value in the range from 0 to 1; CKI is the cytokinetic index S+G2M/G0-1; BC is “1” with increase in the percentage of blast cells in peripheral blood of more than 5.0 %; BC is “0” with a percentage of blast cells in peripheral blood of less than 5.0 %; A – aneuploidy “1” – presence, “0” – absence of a clone in the bone marrow, at P < 0.6 predict a low risk of progression of primary B-cell non-Hodgkin's lymphomas with bone marrow damage, at 0.6≤P≤0.7 predict average risk of progression, with P > 0.7 predict a high risk of progression of primary B-cell non-Hodgkin's lymphomas.

EFFECT: invention can be repeated and used many times in planning the tactics of treatment and monitoring the remission of patients with B-cell non-Hodgkin's lymphomas with bone marrow involvement and reproduced in medical-prophylactic, scientific, medical institutions in oncology.

1 cl, 5 dwg, 7 tbl, 2 ex